The phytotherapeutic potential of Uncaria tomentosa (Willd.) DC. Rubiaceae: scientific and technological monitoring

Evelyne Rolim Braun Simões
Rejane Ramos Machado
Claudia do Ó Pessoa
Lana Grasiela Alves Marques

    Evelyne Rolim Braun Simões

    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology, Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60431-970, CEP 60430-270, Fortaleza, CE, Brazil

    She holds a degree in Pharmacy from the Federal University of Ceará (1988), a Master's in Pharmacology from the UFC (1996) and a PhD in Biotechnology (Innovation Management) - Renorbio from the UFC (2017). As a partner at BiotechCell; it implemented the quality system for the company's Toxicological Testing Platform according to NIT / DICLA 035, providing services to several national industries. She was a substitute professor of Toxicology and Psychophysiology at UFC. She has experience in Tech Monitoring; Priority search, writing and protection of trademarks and patents; and technological prospection using Vantage Point® software. She currently works with consulting and advisory services in the area of Intellectual Property.

    Rejane Ramos Machado

    Oswaldo Cruz Foundation (Fiocruz), Institute of Communication and Scientific and Technological Information in Health (ICICT), Department of Studies in Science and Technology. Avenida Brasil, 4365, Haity Moussachet Pavilion, 2nd floor, Manguinhos, CEP 21045-900, Rio de Janeiro, RJ, Brazil

    Graduated in Librarianship and Documentation from the Federal University of the State of Rio de Janeiro (UNIRIO). Master in Public Health from the Sergio Arouca National School of Public Health at Fiocruz. PhD in Sciences by the Postgraduate Program in Health Information and Communication (PPGICS) at Fiocruz. Employee of the Oswaldo Cruz Foundation. Currently Vice-Leader of the Research Group Democratization of Technical-Scientific Information in Health, working in the lines: Data Mining and Standardization, and History and Metrics. He has experience in the area of ​​Information Science, with an emphasis on information dissemination processes, working mainly on the themes: scientific communication, information technology and communication with appropriation of human-computer interaction methods, but specifically in usability and communicability assessment. She participates in the research project: Sharing research data at Fiocruz with the purpose of optimizing adherence to the open science movement and the elaboration of the data opening policy at Fiocruz.

    Claudia do Ó Pessoa

    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology, Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60431-970, CEP 60430-270, Fortaleza, CE, Brazil.

    Titular Professor of Physiology at the Department of Pharmacology Physiology at UFC - Ceará. CNPq level 1B scholarship holder. Graduated in Biochemical Pharmacy from the Federal University of Pernambuco (1989), master's and doctorate in Pharmacology from the Federal University of Ceará (2000) and post-doctoral degree from the University of British Columbia (2008). Visiting researcher at the National Cancer Institute (NCI-USA) in 2000 and 2004. Senior Visiting Researcher at the John Curtin School of Medical Research - Australian National University- Canberra (2019). Supported by the Institutional Internationalization program ? PRINT- Coordination for the Improvement of Higher Education Personnel- CAPES. It was assigned to Fiocruz Ceará 2014-2018. She currently participates in the CA-BI / CNPq Biotechnology Committee (2018-2023), in the scientific and innovation technical advisory and evaluation chamber of the Ceará Foundation for Support to Technological Scientific Development-FUNCAP (2018-2022). And of the ESF College of Expert Reviewers committee (European Science Foundation (2020-2023). He was vice president of the Federation of Societies of Experimental Biology (FeSBE). He was among the finalists in the X Octávio Frias e Oliveira Award, in the area of ​​oncological innovation For those who make the history of Oncology in the Country Organized by the Cancer Institute of the State of São Paulo and Folha de São Paulo. .com.br/portfolio/claudia-do-o-pessoa/) She is among the women scientists who conduct outstanding research in Ceará (https://diariodonordeste.verdesmares.com.br/editorias/metro/mulheres-cientistas -conduzem-pesquisas-de-destaque-no-ceara-1.2209477) Report: https://agencia.ufc.br/estudo-pioneiro-da-ufc-avalia-papel-de-gene-no-development-de- tumors/. Figure in the TOP 10 000 Scientist BRICS list - AD Scientific Index 2021. https://www.adscientificindex.com/scientist.php?id=1 081375. In 2020, World's Most Influential Scientists, based on SciVerse Scopus, bank of Dutch publisher Elsevier. https://www.ufc.br/noticias/16297-dezoito-cientistas-da-ufc-estao-entre-os-mais-influentes-do-mundo- Segundo-editora-internacional. https://www.ufc.br/noticias/16590-em-alusao-ao-dia-internacional-das-mulheres-e-meninas-na-ciencia-pesquisadoras-falam-sobre-projetos-e-desafios. Founding partner of STARTUP ? 4WBIOTECH. Accelerated by ICC Biolabs. He participated in the CATALISA-SEBRAE program. Approved in the 1st phase of Innovative Women - 2nd FINEP edition. She was Coordinator in the Natural Resources Area, in the RENORBIO Program (2007-2011). Complementary training organized by INPI and WIPO in Good Laboratory Practices, Management of technological innovation in Biotechnology, in technological mapping, technological prospecting, training in intellectual property and technology transfer. The main research activity is experimental oncology and toxicology, using in vitro and in vivo models. In addition to alternative methods of toxicology. It develops bioprospecting activities for natural and synthetic products with anticancer and antioxidant potential, using automated assays: High Throughput Screening (HTS). Coordinator of projects with funding from FINEP, FUNCAP, CAPES, CNPq and BNB. It has collaborations with over 100 national and international researchers, including its national collaboration with Embrapa Agroindústria Tropical - Embrapa, Fundação Oswaldo Cruz- Ceará, in addition to international collaborations with Instituto Fraunhofer IME since 2011 (Achen-Germany), the Australian National University (ANU) since 2010, the National Cancer Institute- USA, since 2001 and British Cancer Research- Vancouver. She coordinates the Inova Saúde-DECIT / MS project in partnership with Biomanguinhos.

    Lana Grasiela Alves Marques

    Federal University of Ceará (UFC), Graduate Program in Biotechnology of Natural Resources, Rua José Aurélio Câmara s/n, Campus do Pici (Bloco 873), CEP 60440-970, Fortaleza, CE, Brazil

    He holds a Bachelor's degree in Chemistry with Technological Attribution from the Federal University of Piauí (2001) and a Master's degree in Chemistry from the Federal University of Piauí (2004), a PhD in Biotechnology from the Northeast Biotechnology Network (RENORBIO), Federal University of Ceará, UFC, with 6 month sandwich period at World Intellectual Property Organization ? WIPO Geneva/Suisse. He developed internship work at Instituto Superior Técnico de Lisboa in the Technology Transfer Area (TT @ IST), Intellectual Property Nucleus (NPI) (2012). He has experience in the field of Chemistry, with an emphasis on Inorganic. Works on the following topics: Intellectual Property, Technological Prospecting. During the internship at NPI, it was possible to obtain knowledge of the Intellectual Property Law of Portugal and the models of Ownership Regulation Agreement; Collaboration Protocol; Intellectual Property Protection Clauses for Research Projects in Consortium of Instituto Superior Técnico de Lisboa (IST). He visited the Biotechnology Park of Cantanhede-Portugal, the BIOCANT PARK. At BIOCANT he participated in the Clustering in Biotechnology Workshop promoted by the Association of Portuguese Business and Innovation Centers / BICS. In 2011, he participated in the Portugal Mission of REDE NIT-NE. The objective of the Portugal Mission was to get to know the Technology Transfer Networks that included the Academic Sector of Portugal, among the institutions visited during the mission: Higher Institute of Economics and Management / UTL; Instituto Superior Técnico Technology Transfer Area ? TT@IST; University Company Association for Development - TECMINHO / University of Minho; Business Association for Innovation - COTEC PORTUGAL; University of Porto - UPIN; Technology Transfer Unit - UATEC / University of Aveiro; Pedro Nunes Institute - IPN / University of Coimbra. Has additional training in Drafting Patents and Patents in Biotechnology by the National Institute of Industrial Property of Portugal (INPI-PT), Project Management; Technological Prospecting; Intellectual Property and Innovation; Negotiation, Commercialization and Contracts; Technological Assessment; Structuring Technological Innovation Centers. All these courses are coordinated by the National Institute of Industrial Property (INPI) Brazil and the World Intellectual Property Organization (WIPO - Geneva). Experience and training in software (Vantage point, Cortellis Competitive Intelligence, Orbit) that carry out technological and scientific exploration in worldwide databases.

Keywords

Uncaria tomentosa
Medicinal plants
Desenvolvimento sustentável
Articles
Patents

Abstract

Medicinal plants are important for pharmacological research and drug development, not only when their constituents are used directly as therapeutic agents, but also as raw materials for synthesis, or models for pharmacologically active compounds. The article proposes a study of the scientific and technological information of the medicinal plant indicated by the Ministry of Health to Uncaria tomentosa, aiming at the development of herbal medicines. For this, the Web of Science and Derwent Innovations Index databases were used. In the analyzes it was possible to observe the growing volume of scientific studies carried out in the world and in Brazil with the plant. The first publications began in the year 1984 and the peak occurred in the year 2005. It should highlight Brazil as responsible for the largest volume in publications. On the other hand, the countries that patent deposited were the United States, China and Japan. Thus, it is possible to affirm the technological potential for the development as herbal medicine of the Uncaria tomentosa plant to be incorporated by the public pharmaceutical industries and distributed in the SUS system.

References

  1. World Health Organization (WHO). Global report on traditional and complementary medicine. Geneva. 2019. 226 p. ISBN: 9789241515436. [Link].
  2. Calixto JB, Dutra RC, Campos MM, Santos AR. Medicinal plants in Brazil: Pharmacological studies, drug discovery, challenges and perspectives. Pharmacol Res. 2016; 112: 4-29. [CrossRef].
  3. World Health Organization (WHO). The World Health Report. Geneva. 1998. 226 p. ISBN: 92 4 156189 0. [Link].
  4. Gia. Herbal supplements and remedies: a global strategic business report. Global Ind Anal; 2013. [Link].
  5. Terra Junior ON, Maldonado JV, Arnobio A. Estudo do desempenho comercial dos insumos farmacêuticos vegetais sob a ótica do comércio exterior. Rev Fitos. Rio de Janeiro. Jul-Set 2015; 9(3): 161-252. [CrossRef] [Link].
  6. Cunha AP, Silva AP, Roque OR, Pereira RO. Plantas e Produtos Vegetais em Fitoterapia. Fundação Calouste Gulbenkian. Serviço de Educação e Bolsas, Lisboa, 2003; 9-11. [Link].
  7. Keplinger K, Laus G, Wurm M, Dierich MP, Teppner H. Uncaria tomentosa (Wild). Ethnomedicinal Uses and new pharmacological, toxicological and botanical results. J Ethnopharmacol. 1999; 64: 23-34. [CrossRef] [PubMed].
  8. Ganzera M, Muhammad I, Khan RA, Khan IA. Improved method for the determination of oxindole alkaloids in Uncaria tomentosa by high performance liquid chromatography. Pl Med. 2004; 67: 447-450. [PubMed].
  9. Desmarchelier C, Mongelli E, Coussio JE, Ciccia G. Evaluation of the in vitro antioxidant activity in extracts of Uncaria tomentosa (Willd.) DC. Phytoth Res. 1997; 11: 254-256. [CrossRef].
  10. Falkiewicz BE, Lukasiak J. Vilcacora [Uncaria tomentosa (Willd.) DC. and Uncaria guianensis (Aublet) Gmell.] - a review of published scientific literature. Case Rep Clinic Pract Revue. 2001; 2: 305-316. [Link].
  11. De Feo V. Medicinal and magical plants in the northern Peruvian Andes. Fitoterapia. 1992; 63: 417-440. [Link].
  12. Reinhard K-H. Uncaria tomentosa (Willd.) DC.: cat's claw, uña de gato, or saventaro. J Alter Compl Med. 1999; 5: 143-151. [CrossRef] [PubMed].
  13. Miranda EM, Sousa JAE, Pereira RCA. Subsídios técnicos para o manejo sustentável da unha de gato (Uncaria spp.) no Vale do Rio Juruá - AC. Ministério da Agricultura, Pecuária e Abastecimento. Embrapa Brasil. Documentos 68. 2001; 1-24. [Link].
  14. Heitzman ME, Neto CC, Winiarz E, Vaisberg AJ, Hammond GB. Ethnobotany, phytochemistry and pharmacology of Uncaria (Rubiaceae). Phytochemistry. 2005; 66: 5-29. [CrossRef] [PubMed].
  15. Prado EG, Gimenez DG, Vazquez RDP, Sanchez JLE, Rodriguez TS. Antiproliferative effects of mitraphylline, a pentacyclic oxindole alkaloidof Uncaria tomentosa on human glioma and neuroblastoma cell lines. Phytomedicine. 2007; 14: 280-284. [CrossRef] [PubMed]
  16. Lemaire I, Assinewe V, Cano P, Awang DV, Arnason JT. Stimulation of inerleukin-1 and-6 production in alveolar macrophages by the neotropical liana, Uncaria tomentosa (uña de gato). J Ethnopharmacol. 1999; 64: 109-115. [CrossRef] [PubMed].
  17. Pilarski R, Zielinski H, Ciesiolka D, Szyfter K, Gulewicz K. Antioxidant activity of ethanolic and aqueous extracts of Uncaria tomentosa (Willd.) DC. J Ethnopharmacol. 2006; 104: 18-23. [CrossRef] [PubMed].
  18. Reis SRIN, Valente LMM, Sampaio AL, Siani AC, Gandini M, Azeredo EL et al. Immunomodulating and antiviral activities of Uncaria tomentosa on human monocytes infected with Dengue Virus-2. Interl Immunopharmacol. 2008; 8: 468-476. [CrossRef] [PubMed].
  19. Gimenez DG, Prado EG, Rodriguez TS, Arche AF, De La Puerta R. Cytotoxic effect of the pentacyclic oxindole alkaloid mitraphylline isolated from Uncaria tomentosa bark on human ewing's sarcoma and breast cancer cell lines. Planta Medica. 2010; 76: 133-136. [CrossRef] [PubMed].
  20. Allen-Hall L, Arnason JT, Cano P, Lafrenie RM. Uncaria tomentosa acts as a potent TNF-alpha inhibitor through NF-kappa B. J Ethnopharmacol. 2010; 127: 685-693. [CrossRef] [PubMed].

Most read articles by the same author(s)

PDF (Portuguese)
HTML (Portuguese)
Save bookmark

Author(s)

  • Evelyne Rolim Braun Simões
    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology, Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60431-970, CEP 60430-270, Fortaleza, CE, Brazil
  • Rejane Ramos Machado
    Oswaldo Cruz Foundation (Fiocruz), Institute of Communication and Scientific and Technological Information in Health (ICICT), Department of Studies in Science and Technology. Avenida Brasil, 4365, Haity Moussachet Pavilion, 2nd floor, Manguinhos, CEP 21045-900, Rio de Janeiro, RJ, Brazil
  • Claudia do Ó Pessoa
    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology, Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60431-970, CEP 60430-270, Fortaleza, CE, Brazil.
  • Lana Grasiela Alves Marques
    Federal University of Ceará (UFC), Graduate Program in Biotechnology of Natural Resources, Rua José Aurélio Câmara s/n, Campus do Pici (Bloco 873), CEP 60440-970, Fortaleza, CE, Brazil

Categories

Metrics

  • Article viewed 546 time(s)

How to Cite

1.
The phytotherapeutic potential of Uncaria tomentosa (Willd.) DC. Rubiaceae: scientific and technological monitoring. Rev Fitos [Internet]. 2022 Mar. 4 [cited 2024 Nov. 22];16(Supl. 2):193-205. Available from: https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/926
Crossref
Scopus
Google Scholar
Europe PMC

1. DIREITOS CEDIDOS - A cessão total não exclusiva, permanente e irrevogável dos direitos autorais patrimoniais não comerciais de utilização de que trata este documento inclui, exemplificativamente, os direitos de disponibilização e comunicação pública da OBRA, em qualquer meio ou veículo, inclusive em Repositórios Digitais, bem como os direitos de reprodução, exibição, execução, declamação, recitação, exposição, arquivamento, inclusão em banco de dados, preservação, difusão, distribuição, divulgação, empréstimo, tradução, dublagem, legendagem, inclusão em novas obras ou coletâneas, reutilização, edição, produção de material didático e cursos ou qualquer forma de utilização não comercial.

2. AUTORIZAÇÃO A TERCEIROS - A cessão aqui especificada concede à FIOCRUZ - FUNDAÇÃO OSWALDO CRUZ o direito de autorizar qualquer pessoa – física ou jurídica, pública ou privada, nacional ou estrangeira – a acessar e utilizar amplamente a OBRA, sem exclusividade, para quaisquer finalidades não comerciais, nos termos deste instrumento.

3. USOS NÃO COMERCIAIS - Usos não comerciais são aqueles em que a OBRA é disponibilizada gratuitamente, sem cobrança ao usuário e sem intuito de lucro direto por parte daquele que a disponibiliza e utiliza.

4. NÃO EXCLUSIVIDADE - A não exclusividade dos direitos cedidos significa que tanto o AUTOR como a FIOCRUZ - FUNDAÇÃO OSWALDO CRUZ ou seus autorizados poderão exercê-los individualmente de forma independente de autorização ou comunicação, prévia ou futura.

5. DIREITOS RESERVADOS - São reservados exclusivamente ao(s) AUTOR(es) os direitos morais sobre as obras de sua autoria e/ou titularidade, sendo os terceiros usuários responsáveis pela atribuição de autoria e manutenção da integridade da OBRA em qualquer utilização. Ficam reservados exclusivamente ao(s) AUTOR(es) e/ou TITULAR(es) os usos comerciais da OBRA incluída no âmbito deste instrumento.

6. AUTORIA E TITULARIDADE - O AUTOR declara ainda que a obra é criação original própria e inédita, responsabilizando-se integralmente pelo conteúdo e outros elementos que fazem parte da OBRA, inclusive os direitos de voz e imagem vinculados à OBRA, obrigando-se a indenizar terceiros por danos, bem como indenizar e ressarcir a FIOCRUZ - FUNDAÇÃO OSWALDO CRUZ de eventuais despesas que vierem a suportar, em razão de qualquer ofensa a direitos autorais ou direitos de voz ou imagem, principalmente no que diz respeito a plágio e violações de direitos.

7. GRATUIDADE - A cessão e autorização dos direitos indicados e estabelecidos neste Instrumento será gratuita, não sendo devida qualquer remuneração, a qualquer título, ao autor e/ou titular, a qualquer tempo.

Report an error